Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
Journal Article (Journal Article;Review)
With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.
Full Text
Duke Authors
Cited Authors
- Heimberger, AB; Sampson, JH
Published Date
- January 2011
Published In
Volume / Issue
- 13 / 1
Start / End Page
- 3 - 13
PubMed ID
- 21149252
Pubmed Central ID
- PMC3018912
Electronic International Standard Serial Number (EISSN)
- 1523-5866
Digital Object Identifier (DOI)
- 10.1093/neuonc/noq169
Language
- eng
Conference Location
- England